Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Here's Why Aaron's (AAN) Is A Hot Investment Pick Right Now

Published 07/09/2019, 09:38 PM
Updated 07/09/2023, 06:31 AM

Aaron's, Inc. (NYSE:AAN) appears to be a solid bet, given its sturdy efforts to remain on growth trajectory. We expect the company to continue gaining from strength in the Progressive (NYSE:PGR) business, which is benefiting from robust invoice volume growth and solid customer base. Also, it remains on track with the transformation of the Aaron’s segment, which bodes well for growth.

Driven by these upsides, shares of this Atlanta, GA-based company have increased approximately 17% in the past six months against the industry’s decline of 3.1%.

This Zacks Rank #1 (Strong Buy) stock has also comfortably outperformed the Retail-Wholesale sector and the S&P 500 Index that advanced 1.9% and 2.4%, respectively, in the said time frame. Further, the stock is hovering close to its 52-week high of $64.49. With a long-term earnings growth rate of 15%, Aaron’s is positioned to attain new highs.

Let’s delve deeper into the major factors that have been driving the company’s performance.

Progressive Business Bodes Well

Aaron's Progressive segment, the company’s virtual lease-to-own business, has been significantly driving its results. This division contributed nearly 51.7% to total revenues in the first quarter of 2019. Robust growth in invoice volume and a solid customer base have been aiding the segment’s performance for the past few quarters. Notably, the segment’s revenues have doubled from $1 billion in 2015 to $2 billion in 2018, while consistently generating strong profits.

The company expects the momentum for the segment to continue in 2019, with estimated revenues of $2,100-$2,175 million and adjusted EBITDA of $260-$275 million.

Turnaround of Aaron’s Business Nears

Aaron’s business is on track with its transformational initiatives, comprising continued investments to improve customer experience, operating efficiencies, compliance and employee engagement. These efforts are likely to place the segment back on its growth trajectory, with sustainable long-term growth in revenues and earnings. Driven by the success of the pilots carried out in 2018, it plans to expand the next generation concept to 40 to 50 locations in 2019, including renovating existing stores and repositioning to new store locations. These new store concepts are poised to lift in-store traffic and revenue.

Additionally, the company’s e-commerce site (Aarons.com) has witnessed significant growth over the years, and is attracting new and younger customers. In 2019, the company expects revenues for the Aaron’s segment to be $1,775-$1,855 million, with adjusted EBITDA of $160-$170 million.

Wrapping Up

The bullish momentum across its business segments has boosted Aaron’s confidence for delivering a stellar performance in fiscal 2019. It projects total sales at $3,905-$4,065 million for the current fiscal, with adjusted EBITDA of $415-$442 million. Further, management expects adjusted earnings of $3.65-$3.85 per share.

We anticipate all aforementioned factors and its robust outlook to help the company remain in investors’ good books.

3 Stocks to Watch

Best Buy Co., Inc. (NYSE:BBY) has a long-term earnings growth rate of 8.8% and a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Target Corporation (NYSE:TGT) has a long-term earnings growth rate of 7.1% and a Zacks Rank #2.

Stitch Fix, Inc. (NASDAQ:SFIX) has a long-term earnings growth rate of 22.5% and a Zacks Rank #2.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>



Aaron's, Inc. (AAN): Free Stock Analysis Report

Best Buy Co., Inc. (BBY): Free Stock Analysis Report

Target Corporation (TGT): Free Stock Analysis Report

Stitch Fix, Inc. (SFIX): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.